Search

Hepatitis C virus (HCV) screening is routine before cardiac transplantation, and virus presence is an exclusion at most centers. Left ventricular assist devices (LVADs) are often used as a bridge to transplantation and cause immune activation. We collected data on 32 consecutive patients undergoing LVAD placement between January 2006 and February 2008 at a single center. Of the 23 potential bridge-to-transplant patients with HCV testing before and after LVAD, seven (30) turned positive for HCV antibody but did not have true HCV infection on confirmatory testing. Cardiac transplant care providers should be aware of possible false-positive HCV antibody tests in this setting.